Beckman Coulter Licenses Roche`s Real Time PCR Patent Portfolio
Beckman Coulter, Inc. has acquired an In Vitro Diagnostics product license to all real-time polymerase chain reaction (PCR) patents and pending patent applications owned or controlled by Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd, Basel, Switzerland. Beckman Coulter will pay Roche a one-time license fee of $27.5 million and will also pay royalties on sales of all licensed products.
"Real-time PCR is the most widely accepted technology for the quantitative amplification and detection in molecular testing," said Scott Garrett, CEO. "We recently announced that Beckman Coulter reached a settlement with Applera Corporation resulting in licenses to Beckman Coulter of the intellectual property needed for development of real time PCR instrumentation for diagnostics. This additional license from Roche gives our company the intellectual property required to meet the molecular testing needs of routine labs for an automated, fully integrated system. Beckman Coulter will continue to build on its strength of simplifying and automating laboratory processes, by bringing its unique capabilities in integrated system development to the area of molecular testing. Development of the products, including instruments and diagnostic kits, will begin immediately. Initial launch is expected in two to three years."
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Scripps Research Scientists Successfully Test New Anti-Obesity Vaccine - Prototype Slows Weight Gain, Reduces Fat in Animal Models
Phenomenex Launches Chiral Screening Service
Significant breakthrough in the chemistry of fluorinated compounds - Overcoming the “Fluoro Wall”: Researchers observe tunneling effect of heavy atoms for the first time
X-rays reveal how glasses lose their stability - PETRA III experiment shows how atoms in glass behave as weaknesses appear
Earlier unknown molecular-level mechanism may contribute to the growth rate of breast cancer
PET points to tau protein as leading culprit in Alzheimer's
Syrris Establish Japanese Subsidiary Office - Syrris Expand Global Sales Network to Match Growing Demand in the Far East
Sartorius reviews fiscal 2008 - Different outlook for the two Group divisions
SGS Australia opens new Sydney Laboratory for Environmental Testing
Thermo Fisher Scientific Announces Partnership with Megaware to Deliver New Bioequivalence Solution
Neandertal genome project reaches its goal - High-quality Neandertal genome provides novel insights into human origins